Industry coverage tracks the money around peptides: Eli Lilly and Novo Nordisk earnings, pipeline shifts, M&A, IPOs, peptide CDMO capacity, and the telehealth and pharmacy economy that GLP-1s built.
The two stories that keep moving the most market cap: how fast oral GLP-1s reach approval (orforglipron, oral semaglutide, oral wegovy, danuglipron's exit), and what happens to the compounded-peptide channel as the FDA tightens. Hims, Ro, LifeMD, GoodRx, and Amazon Pharmacy have all rerouted distribution in the past year. Behind them, contract manufacturers like Bachem, PolyPeptide, and BASF have been the bottleneck no one talked about until they were.
Stories here name the company, the deal, and the dollars. Earnings, partnership, regulatory hit — whatever moved the share price gets covered.
Fast Millennial Mode LLC, founded by entrepreneur Elena Catalina Radu, announced the official launch of Sacred Eye Beauty's flagship 30-Day Ritual on Sunday June 28, 2026. The system has two components. The Inside-Out Activator combines NAD+, spermidine, vitamin C, and MODS Max sublingual-delivery technology in a single daily dose targeting cellular-wellness and healthy-aging markers. The Skin Magic Tablets combine GHK-Cu (copper tripeptide-1), PQQ (pyrroloquinoline quinone), and methylene blue for skin and broader cellular support. The launch fits squarely inside the 2026 mainstream-consumer cosmetic peptide wave that this site has tracked across June: Moes Group's June 6 GHK-Cu private-label manufacturing rollout, CKYN's June 20 GHK-Cu launch, Cosmetics Business's June 2026 feature on eight peptide-anchored beauty launches (Shiseido Ultimune, YSE Beauty Xtreme Glow), and the K-beauty PDRN-peptide-exosome stack. Sacred Eye's differentiator is the inside-out positioning, pairing oral supplementation with topical-equivalent claims. The consumer-channel growth runs in parallel to the regulatory thread: GHK-Cu is one of the seven peptides on the FDA Pharmacy Compounding Advisory Committee's July 23-24 agenda for 503A bulks list eligibility.
STAT News' closing coverage of BIO 2026 in San Diego across two pieces, Alex Hogan's June 26 STATus Report and Damian Garde's June 25 key-takeaways feature, identified two organizing themes that emerged from the four-day convention. First, AI drug discovery shifted from investment-thesis territory to clinical-fact territory: Insilico Medicine's rentosertib (a TNIK inhibitor for idiopathic pulmonary fibrosis where both the target and the compound were identified by generative AI, not a human chemist) became the first peer-reviewed Phase IIa result for a fully AI-discovered drug when results were published in Nature Medicine in 2025 (60 mg once daily produced +98.4 mL mean FVC change versus -20.3 mL placebo across 71 patients). Second, biotech executives at BIO 2026 expressed structural anxiety about Chinese drug development that the industry's primary legislative response, the BIOSECURE Act, does not address: the concern is about the speed and depth of Chinese scientific output rather than about narrow IP or supply-chain risks. The convention's mood reportedly shifted notably from the depressed atmosphere at industry events in 2024-2025 (when capital markets were closed and FDA reviewer turnover was concerning) toward a more constructive engagement with the new operational reality.
Gene-editing pioneer Sangamo Therapeutics filed a voluntary Chapter 11 petition in the US Bankruptcy Court for the District of Delaware on Monday June 23, 2026, after disclosing only $27.6 million in cash as of March 31 and a May 2026 Nasdaq delisting for minimum-bid-price non-compliance. Two simultaneous asset purchase agreements established the floor. Eli Lilly is the stalking-horse bidder at $50 million cash plus assumption of certain liabilities for Sangamo's capsid delivery platform, zinc finger platform, modular integrase (MINT) platform, and prion disease program ST-506. Astellas Pharma takes the Fabry disease asset isaralgagene civaparvovec (ST-920) under a separate agreement. The Lilly bid covers the assets most relevant to the peptide-adjacent neurology pipeline, with prion protein biology offering platform optionality for Lilly's broader neurodegeneration program. Both agreements remain subject to higher-or-better offers under standard Section 363 sale procedures. Sangamo simultaneously cut 51 employees, approximately 40% of its remaining workforce, with the remainder retained through the auction and sale process. The bankruptcy closes a 30-year arc that began as the zinc-finger nuclease pioneer through gene editing's commercial first wave, and underscores that gene-editing platform capital is now consolidating into large-pharma hands.
Hims & Hers Health (NYSE: HIMS) is up roughly 25% in June 2026 on multiple converging investor signals heading into the final week of the month. Novo Nordisk leadership called Hims one of its most 'voluminous' telehealth partners on a recent earnings call, validating the March 2026 branded-supply pact that ended the prior compounded-GLP-1 litigation. Leerink reiterated its Market Perform rating ahead of the July 23-24 FDA Pharmacy Compounding Advisory Committee (PCAC) meeting, framing peptides as the company's next major product category and a key 2027+ growth driver. Barclays raised its price target to $39 from $29 on June 17 with an Overweight rating. CEO Andrew Dudum confirmed Oura Ring integration is 'coming soon,' adding wearable connectivity to the platform. The Hims GLP-1 subscription stack now runs $39 for the first month and $149 monthly thereafter (excluding medication costs), with branded Novo Wegovy injections and pills available alongside the company's owned California compounding-pharmacy capacity for the post-PCAC peptide expansion. The convergence of investor signals (analyst PT raises, Novo validation, PCAC catalyst, wearable integration) makes HIMS one of the most-watched names in the obesity-and-longevity telehealth space heading into Q3 2026.
Cosmetics Business published an industry feature in June 2026 cataloging eight peptide-anchored beauty launches during the year's first half, framing 2026 as the year topical peptide skincare crossed from prestige-only to mass-market shelves. Tracked launches include Shiseido's refreshed Ultimune Power Infusing Oil (a serum-format extension of the brand's signature resilience line), YSE Beauty's Xtreme Glow Dewy Peptide Plumping Serum ($68, the company's best first-day and first-week launch by units), and adjacent product categories anchored on PDRN (polydeoxyribonucleotide), exosomes, and acetyl-hexapeptide and palmitoyl-tripeptide blends. AOL and Glossy parallel coverage flagged the K-beauty PDRN-peptide-exosome stack as the defining ingredient combination for 2026 (matched against retinol on efficacy claims, against snail mucin on heritage positioning). The cosmetic-peptide commercial wave runs alongside the regulatory wave: the FDA peptide categories under PCAC review (BPC-157, KPV, TB-500, MOTS-C, Emideltide, Semax, Epitalon) include several with cosmetic-adjacent claims, and the Moes Group / CKYN / GELITA / Italgel manufacturing pipeline tracked in June digests anchors the supply side.
The 2026 BIO International Convention closed Thursday June 25 at the San Diego Convention Center after four days, 20,000+ industry leaders in attendance, 130+ sessions across 18 focus areas, and a partnering-meeting volume that BIO sources said matched or exceeded prior-year records. Peptide-relevant headline deals across the convention week: the Insilico Medicine + SK Biopharmaceuticals $2.5 billion AI-neuroimmune drug discovery deal on Day 1 (June 22, $18M upfront + $670M per program in development and commercial milestones); BioArctic + Eli Lilly $800 million BrainTransporter blood-brain barrier delivery pact on Day 2 (June 23); STAT News' Day-3 BIO Readout column behind-the-scenes coverage of Eli Lilly's January Chai Discovery AI biologics partnership (June 24); and the disclosed Lilly-Astellas joint stalking-horse bid for Sangamo Therapeutics assets in bankruptcy (capsid delivery platform, zinc finger platform, modular integrase platform, prion disease program ST-506; Astellas takes Fabry disease asset isaralgagene civaparvovec). Fujifilm Life Sciences showcased a continuous electroporation gene delivery system and high-sensitivity in-line Raman measuring system at its Innovation Showcase. BIO 2027 returns to Boston June 7-10, 2027.
Eli Lilly confirmed in reporting on June 22-23, 2026 that it is halving its planned €2.3 billion (US$2.7 billion) investment at the under-construction Alzey, Rhineland-Palatinate injectable manufacturing site, reducing planned headcount from approximately 1,000 to 500 and pushing the redirected capital toward US sites, most likely Lilly's Pennsylvania facility. The plant produces injectable GLP-1 drugs Mounjaro (tirzepatide for type-2 diabetes), Zepbound (tirzepatide for obesity), and Trulicity (dulaglutide), and is still scheduled to open in 2027 at the reduced capacity. Lilly cited Germany's proposed healthcare reform legislation, particularly a 'dynamic manufacturer rebate' that would automatically lower drug reimbursements as utilization climbs. Boehringer Ingelheim is also slashing planned German investment by at least $1 billion, and Pfizer CEO Albert Bourla has signaled a reassessment. Lilly's CEO David Ricks told the German government the company 'can no longer commit to the full vision for Alzey.' The cut arrives the same week as STAT's retatrutide compassionate-use story, sharpening the contrast between Lilly's expanding US capital deployment and tightening European pricing.
STAT News' June 24, 2026 BIO Readout column (Damian Garde, Allison DeAngelis) delivered behind-the-scenes detail on Eli Lilly's January 9, 2026 collaboration with AI startup Chai Discovery for biologics design, plus an update on the Lilly-Astellas joint bid for Sangamo Therapeutics assets in bankruptcy. The Chai Discovery deal deploys the company's Chai-2 zero-shot antibody design model (reportedly achieving double-digit experimental hit rates and full de novo design capability) plus a purpose-built generative AI model trained exclusively on proprietary Lilly data and tailored to Lilly's discovery workflows. Chai closed a $130 million Series B at $1.3 billion valuation in late 2025, eighteen months after launch. On the Sangamo front, Lilly is in line to acquire Sangamo's capsid delivery platform, zinc finger platform, modular integrase platform, and prion disease program ST-506 in the bankruptcy auction; Astellas is positioned to take Fabry disease asset isaralgagene civaparvovec. BIO 2026 runs June 22-25 at the San Diego Convention Center.
Hims & Hers Health (NYSE: HIMS) broke above $30 on June 22, 2026 for the first time since April, finishing the month +36% — its best month since March — on rising investor confidence in the company's peptide platform ahead of the July 23-24 FDA Pharmacy Compounding Advisory Committee (PCAC) meeting. Leerink called the PCAC meeting a key catalyst, framing peptides as Hims' next major product category supporting growth beyond 2027. FirstWave Fund CEO Jonah Lupton projected Hims could generate $10-19 billion in annual peptide-related revenue by 2030 if it captures 4-5% of the combined GLP-1 and non-GLP-1 peptide markets. Hims acquired a California peptide manufacturing facility in 2025 and added in-house lab testing capabilities. CEO Andrew Dudum confirmed Oura Ring integration is 'coming soon,' signaling deeper wearable connectivity. The June 22-23 stock move reflects the broader market consensus that PCAC will reclassify the seven peptides under review (BPC-157, KPV, TB-500, MOTS-C, Emideltide, Semax, Epitalon) and open compounding-pharmacy supply channels.
BioArctic (Nasdaq Stockholm: BIOA b) announced on June 22, 2026 a research and collaboration agreement with Eli Lilly combining BioArctic's proprietary BrainTransporter technology — transferrin-receptor-mediated active transport across the blood-brain barrier — with an undisclosed Lilly proprietary molecule in neurodegeneration. BioArctic receives $30M upfront, eligibility for milestone payments up to $770M (total potential value ~$800M), plus tiered mid-single-digit royalties on global net sales. BioArctic will generate the new drug candidate combining the technology with Lilly's molecule; Lilly assumes full global development and commercialization responsibility. This is BioArctic's fourth BrainTransporter partnership, after collaborations with Bristol Myers Squibb (Alzheimer's), AbbVie, and an undisclosed partner. The deal signals continued big-pharma demand for blood-brain-barrier delivery platforms as neurodegeneration competition intensifies post-leqembi.
Indena and Chemi S.p.A. (Italfarmaco Group) announced a strategic partnership in June 2026 combining peptide chemistry and high-potency API (HPAPI) conjugation expertise to position both firms as development and manufacturing partners for biotech and pharmaceutical companies pursuing peptide-drug conjugates (PDCs). Under the agreement, Chemi supplies the peptide carrier molecules and Indena handles the conjugation with highly potent payload molecules. Neither company is developing proprietary PDC drugs; the partnership reflects the broader CDMO consolidation pattern as the PDC modality scales (six PDCs in Phase 3 trials and ~96 in development globally per the April 2026 ResearchAndMarkets report, with Lutathera as the only FDA-approved standalone PDC after Pepaxto's withdrawal and the Pepaxti EMA expansion application pending). The partnership lands alongside CordenPharma's AmbioPharm acquisition and the broader sector reshaping.
CKYN LLC, a Kirkland, Washington-based skincare company, launched The Complete CKYN Protocol on June 20, 2026 — a three-step daily skincare system built entirely around GHK-Cu (Copper Tripeptide-1). The protocol comprises the Morning GHK-Cu Perfecting Lotion, Daytime GHK-Cu Tallow Balm, and Night-Time GHK-Cu Firming Serum. The product positioning anchors on six bioactives instead of the typical 20+ ingredient prestige skincare formulation, with concentrations targeted to clinical-study levels: published GHK-Cu research has shown 22% visibly firmer skin and 16% reduction in fine-line appearance after 12 weeks of consistent twice-daily application. GHK-Cu was first isolated from human plasma in 1973 by Dr. Loren Pickart and has accumulated four decades of cosmetic-science evidence. CKYN sits alongside Italgel avvera (June 12 launch) and GELITA CURADERM (Vitafoods Europe 2026) in the active 2026 cosmetic-peptide launch cycle.
Pfizer announced on June 18, 2026 (8-K filed) that Chief Financial Officer Dave Denton will step down from his role and leave the company on August 15 for a professional opportunity outside the pharmaceutical industry in consumer goods. Cecile Guegan, currently Senior Vice President, Finance, Global Biopharmaceutical Business (joined Pfizer in 2005, current role since 2022), was named Interim CFO effective August 16 while Pfizer conducts internal and external search. The same June 18 8-K reaffirmed 2026 guidance: revenues of $59.5-62.5B and adjusted diluted EPS of $2.80-3.00. Pfizer also presented detailed berobenatide (PF'3944) Phase 2b VESPER-1/-2/-3 data at the ADA Scientific Sessions June 6 supporting monthly dosing for the first-in-class GLP-1 RA peptide and confirmed plans for 10 Phase 3 studies in 2026 as part of a 20+ obesity-trial program. PFE stock dropped 3% on the CFO surprise.
Biogen (Nasdaq: BIIB) completed its $5.6B acquisition of Apellis Pharmaceuticals on May 14, 2026 after the May 13 tender offer closed at 82.4% of outstanding common stock at $41 per share in cash plus contingent value rights (up to $4 per share tied to SYFOVRE global net sales milestones). The transaction brings two commercialized peptide-based products into Biogen's portfolio: pegcetacoplan (EMPAVELI), a pegylated cyclic 13-amino-acid peptide complement C3 inhibitor approved for paroxysmal nocturnal hemoglobinuria (PNH) and C3 glomerulopathy / immune complex-membranoproliferative glomerulonephritis; and SYFOVRE, the intravitreal pegcetacoplan formulation for geographic atrophy secondary to age-related macular degeneration. Combined 2025 net product revenue was $689M. Biogen expects the deal to be Non-GAAP EPS accretive in 2027 and to materially increase Biogen's compound annual growth rate through end of decade. The deal restores a meaningful peptide-modality presence to Biogen's portfolio.
The BIO International Convention opens Monday June 22 in San Diego through Thursday June 25, drawing 20,000+ industry leaders across 130+ sessions in 18 focus areas — the year's largest peptide-and-biopharma deal-making and pipeline conference. Among the opening-day announcements: Insilico Medicine and SK Biopharmaceuticals will formally announce a research and development collaboration to discover AI-enabled innovative drug candidates in the neuroimmune CNS area, with Insilico eligible for up to $18M in upfront and near-term milestone payments and total potential deal value exceeding $2.5B including development, regulatory, and commercial milestones plus single-digit royalties. The pact sets a record for Insilico's APAC partnership totals. Industry watchers will track BIO 2026's deal-making cadence as the post-ADA / post-ENDO cycle concludes and the FDA PCAC peptide-compounding decision (July 23-24) becomes the next major regulatory catalyst.
Bachem AG (SIX: BANB) announced May 25, 2026 that Chief Commercial Officer Torsten Wöhr decided to pursue a new opportunity outside the company. CEO Anne-Kathrin Stoller — who succeeded Thomas Meier as CEO on January 1, 2026 after 19 years at Bachem in increasingly senior roles (Head of Business Development & Sales Europe, Chief Marketing Officer, COO Americas) — assumed the CCO role in addition to her CEO responsibilities until a successor is appointed. Bachem is one of two major peptide CDMOs supplying the global GLP-1 API market alongside PolyPeptide; the company is in the middle of multi-site capacity expansion across Switzerland (Bubendorf Module I completion H1 2026) and the US (San Diego, King of Prussia). The CCO transition follows months of senior turnover and comes as GLP-1 manufacturing capacity has become the rate-limiting constraint for the entire commercial peptide industry.
Pharmaceutical Technology's June 19, 2026 Weekly Roundup centered on two peptide-manufacturing best-practices features. Ajoy Koppolu argued that successful peptide manufacturing in prefilled syringes for high-speed autoinjectors requires a coordinated lifecycle approach integrating formulation design, Cpk-driven quality control, and factory acceptance testing to ensure consistent, compliant dose delivery — increasingly the bottleneck as injectable GLP-1, amylin, and triple-agonist peptides enter commercial scale. Separately, Elizabeth Hickman (CEO of AusteinPX) argued that early formulation and manufacturing decisions drive up to 80% of a drug's environmental impact, and that solvent-free, fusion-based alternatives to traditional spray-dried dispersion offer simultaneous operational and environmental gains — relevant as PolyPeptide and EMA both pursue greener GLP-1 manufacturing pathways.
Coverage week of June 15-19 distilled the post-ADA market share story: Eli Lilly's tirzepatide franchise (Mounjaro for T2D, Zepbound for obesity) now holds 54.8% of US GLP-1 prescription share versus 47% a year earlier, with Q1 2026 YoY growth of 125% for Mounjaro and 80% for Zepbound and full-year revenue guidance raised to $82-85B. Novo Nordisk lifted its own 2026 guidance to a 4-12% currency-adjusted decline (improved from 5-13%) on Wegovy pill momentum (3M US scripts in five months, 65% of new prescriptions, 82% to GLP-1-naive patients), but Novo's stock has declined 42% over the past year against Lilly's 40% gain — the share-shift signal the ADA cycle crystallized. Lilly's seven additional retatrutide Phase 3 readouts across 2026 (TRIUMPH-7 chronic low-back pain, TRIUMPH-8 general obesity, TRIUMPH-9 obesity without T2D, plus OSA, MASLD, and cardiometabolic outcomes) extend the franchise gap.